According to intranasal drug developer Impel NeuroPharma, the company has signed service agreements with 505(b)(2) development specialist Camargo Pharmaceutical Services. Camargo will provide development services for products based on Impel's Precision Olfactory Delivery (PODTM) intranasal delivery platform. In December 2016, Impel announced that it had raised up … [Read more...] about Impel NeuroPharma announces agreement with Camargo Pharmaceutical Services
Business
MannKind launches Afrezza titration pack, expands sales force
MannKind Corporation has announced the availability of a new titration pack which includes 60 each of 4, 8, and 12 unit cartridges of Afrezza inhalation powder. The company already offers a titration pack that includes 90 each of 4 and 8 unit cartridges, which it says accounts for nearly 25% of Afrezza units dispensed on a weekly basis. According to the company, … [Read more...] about MannKind launches Afrezza titration pack, expands sales force
Beximco joint venture with BioCare includes new GMP inhaler facility
Bangladeshi generics company Beximco Pharmaceuticals announced that it has entered into a joint venture with Malaysian pharma company BioCare and said that the first joint project, an MDI manufacturing facility in Seri Iskandar Pharmaceutical Park, Perak, Malaysia, has already received GMP approval from the Malaysian Ministry of Health. Beximco, which will own 30% … [Read more...] about Beximco joint venture with BioCare includes new GMP inhaler facility
Pulmatrix announces $5 million registered direct offering
Inhaled drug developer Pulmatrix has announced an agreement to sell approximately 2 million shares of its common stock to institutional investors at $2.50 per share in a registered direct offering expected to generate net proceeds of approximately $4.5 million. Closing is expected on February 2, 2017, the company said, and proceeds will be used to pay indebtedness … [Read more...] about Pulmatrix announces $5 million registered direct offering
Cipla launches the Synchrobreathe inhaler in South Africa
Cipla has launched its Synchrobreathe breath actuated inhaler in South Africa, the company announced. In 2015, Cipla had said that it expected to launch the inhaler by the end of that year. Cipla Medpro CEO Paul Miller said, “Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South … [Read more...] about Cipla launches the Synchrobreathe inhaler in South Africa
NasoShield developer Altimmune to merge with PharmAthene
Altimmune, which is developing intranasal vaccines against influenza and anthrax, is set to merge with vaccine developer PharmAthene, the companies have announced. Altimmune will become a wholly-owned subsidiary of PharmAthene subject to stockholder approval of the all-stock transaction, and the combined company will operate under the name Altimmune. After years … [Read more...] about NasoShield developer Altimmune to merge with PharmAthene
Mast Therapeutics to merge with Savara
AIR001 developer Mast Therapeutics will merge with AeroVanc and Molgradex developer Savara, the companies have announced. Savara's current management team will lead the combined company, which will be called Savara Inc and which will trade under a new stock ticker symbol. After the merger, current Savara stockholders will own ~76% of the combined company, and current … [Read more...] about Mast Therapeutics to merge with Savara
Satsuma Pharmaceuticals spins out from SNBL to develop intranasal dihydroergotamine
Satsuma Pharmaceuticals, a spin out from Shin Nippon Biomedical Laboratories (SNBL) has closed a $12 million Series A financing co-led by RA Capital Management and TPG Biotech, the company said. Proceeds will be used to fund development of the company's STS101 dihydroergotamine (DHE) intranasal dry powder for the treatment of migraines. In 2013, SNBL announced … [Read more...] about Satsuma Pharmaceuticals spins out from SNBL to develop intranasal dihydroergotamine
BAT returns Voke inhaler rights to Kind Consumer
Days after its subsidiary Nicovations cancelled supply agreements with Bespak, British American Tobacco says that it and Kind Consumer "have reached a mutually satisfactory agreement on the financial aspects" on "a new approach to commercialize the Voke nicotine inhaler" in which BAT will return the rights to the inhaler to Kind, "allowing Kind to embrace the full … [Read more...] about BAT returns Voke inhaler rights to Kind Consumer
Nicovations terminates Bespak supply agreements for Voke nicotine inhaler
Bespak parent company Consort Medical has confirmed that British American Tobacco subsidiary Nicovations has terminated its supply agreements with Bespak for the Voke nicotine inhaler, effective immediately. According to Consort, Nicovations invoked a clause in the agreement allowing it to cancel in the event that the product failed to reach commercial launch by 31 … [Read more...] about Nicovations terminates Bespak supply agreements for Voke nicotine inhaler